Darwin Biosciences

Darwin Biosciences has developed a breakthrough, self-contained point-of-care diagnostic device that uses saliva to detect the immune signature of acute infections, independent of laboratories or power. Originating from military-funded research, the platform is initially targeting the critical need for early sepsis detection, where timely diagnosis can significantly reduce mortality. The company, which has raised $17 million, is pursuing strategic partnerships to adapt its scalable nucleic acid detection platform for various disease areas, positioning it as a foundational technology for next-generation diagnostics.

A self-contained, power-independent point-of-care device that uses saliva to detect a host immune response biomarker panel indicative of acute-phase infection. The platform leverages RNA amplification and is adaptable for targeted nucleic acid detection.

Competes with established lab-based sepsis biomarker tests (e.g., PCT, lactate) and emerging POC molecular tests. Broader competition includes other POC molecular diagnostic platforms (e.g., Cepheid, Abbott ID Now), though Darwin's power independence and saliva sample are key differentiators.